Literature DB >> 29119480

Rheumatoid factor false positivity in patients with ANCA-associated vasculitis not having medical conditions producing rheumatoid factor.

Jae-Seung Moon1, Diane Da-Hyun Lee2,3, Yong-Beom Park2, Sang-Won Lee4.   

Abstract

We investigated the rate of rheumatoid factor (RF) false positivity at diagnosis and its influence on clinical and prognostic features and rheumatoid arthritis (RA) development during the follow-up in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients without RA or other medical conditions triggering RF false positivity. We reviewed the medical records of 128 AAV patients. We divided patients with AAV and each variant into two groups according to RF positivity and compared variables between the two groups. Odds ratio and cumulative relapse-free survival rate were obtained by multivariate logistic regression analysis and the Kaplan-Meier survival analysis, respectively. The mean age at diagnosis was 53.6 years and 41 patients were male. Of 128 AAV patients, 69 patients (53.9%) were classified as microscopic polyangiitis (MPA), 29 (22.7%) as granulomatosis with polyangiitis (GPA) and 30 (23.4%) as eosinophilic GPA (EGPA). The rate of RF false positivity was 39.1% in AAV patients. On univariate analysis, general, cutaneous and mucous and ocular manifestations and myeloperoxidase (MPO)-ANCA (or perinuclear (P)-ANCA) positivity were associated with RF false positivity in patients with AAV. On multivariate analysis, cutaneous manifestation was the only independent predictor of RF false positivity in EGPA patients. RF false positivity had no influence on cumulative relapse-free survival rate of AAV or RA development during the follow-up. RF false positivity rate was 39.1% in AAV patients and it was associated with cutaneous manifestation in EGPA patients at diagnosis, but not relapses of AAV or RA development during the follow-up.

Entities:  

Keywords:  ANCA-associated vasculitis; False positivity; Manifestation; Prognosis; Rheumatoid factor

Mesh:

Substances:

Year:  2017        PMID: 29119480     DOI: 10.1007/s10067-017-3902-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  27 in total

1.  A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Authors:  J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani
Journal:  Arthritis Rheum       Date:  2001-04

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Correlation between rheumatoid factor and peripheral eosinophil count in chronic eosinophilic pneumonia.

Authors:  Megumi Kudou; Hirotaka Yasuba; Yoshiki Kobayashi; Kazuyuki Hamada; Hideo Kita
Journal:  Respirology       Date:  2006-11       Impact factor: 6.424

4.  Protective role of rheumatoid factor in lupus nephritis.

Authors:  T L Skare; M B G Silva; A P Holler; P A Chavez
Journal:  Clin Exp Rheumatol       Date:  2009 Sep-Oct       Impact factor: 4.473

5.  Chronic eosinophilic pneumonia (Carrington's disease) and rheumatoid arthritis.

Authors:  Laurence Boudou; Christian Alexandre; Thierry Thomas; Béatrice Pallot-Prade
Journal:  Joint Bone Spine       Date:  2010-06-02       Impact factor: 4.929

Review 6.  Diagnostic accuracy of combined tests of anti cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis: a meta-analysis.

Authors:  Jianhong Sun; Yuhui Zhang; Lei Liu; Gang Liu
Journal:  Clin Exp Rheumatol       Date:  2013-09-18       Impact factor: 4.473

7.  European consensus statement on the terminology used in the management of lupus glomerulonephritis.

Authors:  C Gordon; D Jayne; C Pusey; D Adu; Z Amoura; M Aringer; J Ballerin; R Cervera; J Calvo-Alén; C Chizzolini; Jm Dayer; A Doria; F Ferrario; J Floege; L Guillevin; M Haubitz; F Hiepe; F Houssiau; P Lesavre; L Lightstone; Pl Meroni; O Meyer; B Moulin; K O'Reilly; M Praga; H Schulze-Koops; Ra Sinico; Kgc Smith; A Tincani; C Vasconcelos; G Hughes
Journal:  Lupus       Date:  2009-03       Impact factor: 2.911

8.  Rheumatoid factor, cryoglobulinemia, anti-DNA, and renal disease in patients with systemic lupus erythematosus.

Authors:  T W Howard; M J Iannini; J J Burge; J S Davis
Journal:  J Rheumatol       Date:  1991-06       Impact factor: 4.666

9.  Analysis of rheumatoid factor according to various hepatitis B virus infectious statuses.

Authors:  S T Choi; H W Lee; J S Song; S K Lee; Y B Park
Journal:  Clin Exp Rheumatol       Date:  2013-10-21       Impact factor: 4.473

10.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01
View more
  5 in total

1.  Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience.

Authors:  Bashar Fteiha; Alon Bnaya; Marwan Abu Sneineh; Gideon Nesher; Gabriel Simon Breuer
Journal:  Intern Emerg Med       Date:  2020-10-06       Impact factor: 3.397

2.  ANCA-Associated Vasculitis Clinical Presentation and Clinical Predictors of Relapse in Saudi Arabia.

Authors:  Hana Alahmari; Hana Al Daajani; Fatimah Alsayed; Abdulrhaman Alrashid
Journal:  Open Access Rheumatol       Date:  2021-07-17

3.  Patients with ANCA-Associated Glomerulonephritis and Connective Tissue Diseases: A Comparative Study from the Maine-Anjou AAV Registry.

Authors:  Fanny Guibert; Anne-Sophie Garnier; Samuel Wacrenier; Giorgina Piccoli; Assia Djema; Renaud Gansey; Julien Demiselle; Benoit Brilland; Maud Cousin; Virginie Besson; Agnès Duveau; Khuzama El Nasser; Jean-Philippe Coindre; Anne Croue; Jean-Paul Saint-André; Alain Chevailler; Jean-François Subra; Jean-François Augusto
Journal:  J Clin Med       Date:  2019-08-14       Impact factor: 4.241

Review 4.  Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature.

Authors:  Inge C Van Gool; Jesper Kers; Jaap A Bakker; Joris I Rotmans; Y K Onno Teng; Martijn P Bauer
Journal:  Clin Rheumatol       Date:  2022-06-23       Impact factor: 3.650

5.  Subtypes in eosinophilic granulomatosis with polyangiitis classified according to rheumatoid factor.

Authors:  Jun Inamo; Yuko Kaneko; Yuichiro Ota; Tsutomu Takeuchi
Journal:  Clin Rheumatol       Date:  2019-07-17       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.